The Senate Health, Education, Labor and Pensions (HELP) Committee recently held a hearing entitled, “Examining Oversight Reports on the 340B Drug Pricing Program” to coincide with the release of findings from the U.S. Government Accountability Office (GAO) regarding their efforts to improve oversight for the program. Most of the witness testimony focused on the lack […]
Rep. Carter (R-GA-1) introduced the 340B Optimization Act on April 24, 2018 to increase transparency and ultimately improve care for low income patients. What does the 340B Optimization Act require? The 340B Optimization Act would require certain disproportionate share hospital (DSH) covered entities to annually report on their low-income utilization rate of outpatient hospital services […]
Along with following the Congressional and regulatory activity on the 340B drug pricing program, it is also important to keep abreast of recent analyses of the program in the peer-reviewed literature. The New England Journal of Medicine article, “Consequences of the 340B Drug Pricing Discount Program” examines concerns about the 340B discount program, specifically those […]
The 340B program has grown beyond its original intent and the lack of transparency about how hospitals are using their savings is of growing concern. In November 2017, CMS issued their Medicare Hospital Outpatient Prospective Payment System (OPPS) Final Rule for CY 2018 (82 FR 59216) which implemented a payment reduction for most covered outpatient […]
Read our latest specialty pharmacy insight report here.